Comparable stake leader
BlackRock, Inc.
SEC ownership of CVS HEALTH Corp
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0000064803.
Disclosed value leader
BlackRock, Inc.
Comparable rows
50/50
Latest evidence
30 Jun 2026
- Public ticker
- CVS on NYSE
- Parsed ownership sources
-
13F, 13D/G, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
BlackRock, Inc.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
BlackRock, Inc.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0000064803
- Issuer location
- Woonsocket, RI
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of CVS HEALTH Corp (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
BlackRock, Inc.
Disclosed value leader
BlackRock, Inc.
Comparable rows
50/50
Latest evidence
30 Jun 2026
13F
13D/G
3/4/5
Lead comparable stake: 8.3%
13D/G row: BlackRock, Inc.
Showing 1-8 of 50 holder rows.
Quick read
BlackRock, Inc. leads the comparable SEC ownership view at 8.3%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens BlackRock, Inc.'s linked filing trail.
Comparable ownership
Top 5
BlackRock, Inc.
8.3%
VANGUARD CAPITAL MANAGEMENT LLC
7.5%
Capital World Investors
5.5%
DODGE & COX
3.9%
Jeffrey R. Balser
0%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| BlackRock, Inc. |
13F
13D/G
Company
|
8.3%
from 13D/G
|
$12,747,461,705
123,223,409 shares
|
— | 30 Jun 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13F
13D/G
Company · Vanguard Capital Management
|
7.5%
from 13D/G
|
$8,618,974,924
83,315,369 shares
|
— | 30 Jun 2026 |
| Capital World Investors |
13F
13D/G
Company
|
5.5%
from 13D/G
|
$7,753,834,783
74,951,955 shares
|
— | 30 Jun 2026 |
| DODGE & COX |
13D/G
13F
Company
|
3.9%
|
$5,296,351,814
50,012,765 shares
|
$0 | 30 Jun 2026 |
| Jeffrey R. Balser |
3/4/5
Director
|
0%
|
$1,128,794
15,717 shares
|
— | 14 May 2026 |
| Guy P. Sansone |
3/4/5
Director
|
0%
|
$1,084,938
15,106 shares
|
— | 14 May 2026 |
| J. Scott Kirby |
3/4/5
Director
|
0%
|
$1,036,649
14,434 shares
|
— | 14 May 2026 |
| Fernando Aguirre |
3/4/5
Director
|
0%
|
$755,043
10,513 shares
|
— | 20 May 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$358,973,073.
Buys
$0
Insiders: 0
Sells
$358,973,073
Insiders: 2
Net
-$358,973,073
Shares: -3,819,551
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 3,819,551
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 3,819,551 | $0 | $358,973,073 | -$358,973,073 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 42 reporting-owner rows connected to CVS HEALTH Corp. Open a relationship link for the CIK-to-CIK filing trail.
Rows
42
Largest Forms 3/4/5 holder
Larry Robbins
Net 12M change
-$358,973,073
Latest report
26 Jun 2026
Recent insider transactions for CVS HEALTH Corp
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| James D. Clark | CVS | Common Stock (Restricted) | Tax liability | -1.62% | -454 | 27,606 | 26 Jun 2026 | Direct | ||
| Brian Newman | CVS | Common Stock | Tax liability | -45.2% | -2,478 | 3,008 | 31 May 2026 | Direct | ||
| Amy Compton-Phillips | CVS | Common Stock | Tax liability | -44.4% | -7,618 | 9,557 | 31 May 2026 | Direct | ||
| Fernando Aguirre | CVS | Common Stock | Disposed to Issuer | -12.9% | -1,563 | 10,513 | 21 May 2026 | Direct | ||
| Larry M. Robbins | CVS | Common Stock | Sale | -7.13% | $34,619,007 | $93.45 | -370,462 | 4,824,799 | 21 May 2026 | Held by Glenview Investment Funds |
| Larry M. Robbins | CVS | Cash-Settled Swaps | Sale | -100% | $35,271,558 | $93.31 | -378,000 | 0 | 21 May 2026 | Held by Glenview Investment Funds |
| Fernando Aguirre | CVS | Common Stock | Disposed to Issuer | -71.6% | -30,437 | 12,076 | 20 May 2026 | Direct | ||
| Larry M. Robbins | CVS | Common Stock | Sale | -16.4% | $95,510,822 | $93.82 | -1,018,000 | 5,195,261 | 20 May 2026 | Held by Glenview Investment Funds |
| Larry M. Robbins | CVS | Common Stock | Sale | -24.2% | $187,341,308 | $94.45 | -1,983,538 | 6,213,261 | 19 May 2026 | Held by Glenview Investment Funds |
| John E. Gallina | CVS | Deferred Stock Units | Award | 1,448 | 1,448 | 14 May 2026 | Direct | |||
| Michael F. Mahoney | CVS | Deferred Stock Units | Award | 37% | 1,737 | 6,429 | 14 May 2026 | Direct | ||
| Fernando Aguirre | CVS | Common Stock | Award | 3.82% | 1,563 | 42,513 | 14 May 2026 | Direct | ||
| Jeffrey R. Balser | CVS | Common Stock | Award | 15.1% | 2,058 | 15,717 | 14 May 2026 | Direct | ||
| J. Scott Kirby | CVS | Common Stock | Award | 11.1% | 1,447 | 14,434 | 14 May 2026 | Direct | ||
| Leslie V Norwalk | CVS | Common Stock | Award | 24.4% | 1,447 | 7,376 | 14 May 2026 | Direct | ||
| Guy P. Sansone | CVS | Common Stock | Award | 10.6% | 1,447 | 15,106 | 14 May 2026 | Direct | ||
| Alecia A. DeCoudreaux | CVS | Deferred Stock Units | Award | 3.55% | 1,448 | 42,182 | 14 May 2026 | Direct | ||
| Anne M. Finucane | CVS | Deferred Stock Units | Award | 9.18% | 1,544 | 18,355 | 14 May 2026 | Direct | ||
| C. David Brown II | CVS | Common Stock | Award | 1.21% | 1,544 | 129,316 | 14 May 2026 | Direct | ||
| Douglas H. Shulman | CVS | Deferred Stock Units | Award | 1,448 | 1,448 | 14 May 2026 | Direct | |||
| Larry M. Robbins | CVS | Deferred Stock Units | Award | 23.5% | 1,930 | 10,148 | 14 May 2026 | Direct | ||
| Tilak Mandadi | CVS | Common Stock | Sale | -87.3% | $6,230,379 | $89.58 | -69,551 | 10,133 | 08 May 2026 | Direct |
| Prem S. Shah | CVS | Common Stock | Tax liability | -2.25% | -1,484 | 64,356 | 01 Apr 2026 | Direct | ||
| Steven H. Nelson | CVS | Common Stock | Tax liability | -45.6% | -2,432 | 2,900 | 01 Apr 2026 | Direct | ||
| Tilak Mandadi | CVS | Common Stock | Tax liability | -4.36% | -3,634 | 79,684 | 01 Apr 2026 | Direct | ||
| Samrat S. Khichi | CVS | Common Stock | Tax liability | -9.58% | -3,541 | 33,421 | 01 Apr 2026 | Direct | ||
| J. David Joyner | CVS | Common Stock | Tax liability | -10.2% | -8,029 | 70,349 | 01 Apr 2026 | Direct | ||
| James D. Clark | CVS | Common Stock | Tax liability | -17.4% | -3,262 | 15,457 | 01 Apr 2026 | Direct | ||
| Heidi B. Capozzi | CVS | Common Stock | Tax liability | -9.29% | -1,334 | 13,023 | 01 Apr 2026 | Direct | ||
| Prem S. Shah | CVS | Common Stock (Restricted) | Award | 66.3% | 25,062 | 62,852 | 31 Mar 2026 | Direct | ||
| Prem S. Shah | CVS | Stock Option | Award | 161,676 | 161,676 | 31 Mar 2026 | Direct | |||
| Brian Newman | CVS | Common Stock (RSUs) | Award | 89.2% | 19,493 | 41,354 | 31 Mar 2026 | Direct | ||
| Brian Newman | CVS | Stock Option | Award | 125,748 | 125,748 | 31 Mar 2026 | Direct | |||
| Steven H. Nelson | CVS | Common Stock (Restricted) | Award | 104.4% | 22,277 | 43,606 | 31 Mar 2026 | Direct | ||
| Steven H. Nelson | CVS | Stock Option | Award | 143,712 | 143,712 | 31 Mar 2026 | Direct | |||
| Tilak Mandadi | CVS | Common Stock (RSUs) | Award | 33.6% | 22,277 | 88,543 | 31 Mar 2026 | Direct | ||
| Tilak Mandadi | CVS | Stock Option | Award | 143,712 | 143,712 | 31 Mar 2026 | Direct | |||
| Samrat S. Khichi | CVS | Common Stock (Restricted) | Award | 48.9% | 12,531 | 38,139 | 31 Mar 2026 | Direct | ||
| Samrat S. Khichi | CVS | Stock Option | Award | 80,838 | 80,838 | 31 Mar 2026 | Direct | |||
| J. David Joyner | CVS | Common Stock (RSUs) | Award | 115.8% | 86,326 | 160,860 | 31 Mar 2026 | Direct | ||
| Amy Compton-Phillips | CVS | Common Stock (RSUs) | Award | 10.5% | 5,569 | 58,660 | 31 Mar 2026 | Direct | ||
| Amy Compton-Phillips | CVS | Stock Option | Award | 35,928 | 35,928 | 31 Mar 2026 | Direct | |||
| James D. Clark | CVS | Common Stock (Restricted) | Award | 45.6% | 11,138 | 35,539 | 31 Mar 2026 | Direct | ||
| James D. Clark | CVS | Stock Option | Award | 11,976 | 11,976 | 31 Mar 2026 | Direct | |||
| Heidi B. Capozzi | CVS | Common Stock (Restricted) | Award | 13.5% | 10,025 | 84,450 | 31 Mar 2026 | Direct | ||
| Heidi B. Capozzi | CVS | Stock Option | Award | 64,670 | 64,670 | 31 Mar 2026 | Direct | |||
| John E. Gallina | CVS | Common Stock | Award | 582 | 582 | 19 Mar 2026 | Direct | |||
| Samrat S. Khichi | CVS | Common Stock | Tax liability | -20.9% | -7,886 | 29,775 | 28 Feb 2026 | Direct | ||
| J. David Joyner | CVS | Common Stock | Tax liability | -3.74% | -1,944 | 49,996 | 28 Feb 2026 | Direct | ||
| Prem S. Shah | CVS | Common Stock | Tax liability | -0.4% | -247 | 61,509 | 01 Jan 2026 | Direct |
* marks a reported price that did not pass the local price check.